Preeclampsia Diagnostics Market is Estimated To Witness High Growth Owing To increased implementation of prenatal screening practices

raj11

posted on 9 months ago — updated on 1 second ago

76
views

Preeclampsia Diagnostics Market is Estimated To Witness High Growth Owing To increased implementation of prenatal screening practices

Preeclampsia diagnostics include tests and assays to detect presence of preeclampsia in pregnant women.

The Preeclampsia Diagnostics Market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Preeclampsia diagnostics include tests and assays to detect presence of preeclampsia in pregnant women. It involves blood and urine tests to check blood pressure, detect protein in urine, and measure liver enzymes and platelet count. Early diagnosis is important to monitor the condition and prevent severe complications in both mother and baby.

Market key trends:
The preeclampsia diagnostics market is witnessing high growth owing to increased implementation of prenatal screening practices and awareness about the condition. Preeclampsia is a common pregnancy complication characterized by high blood pressure. According to World Health Organisation, approximately 14% of all maternal deaths globally are directly caused by preeclampsia and eclampsia. Hence, various government initiatives promoting routine antenatal checkups are driving the adoption of preeclampsia diagnostic tests. Furthermore, ongoing research & development and new product launches by leading manufacturers will contribute to the market growth during the forecast period.

Porter's Analysis
Threat of new entrants: Low capital requirements and established brands lower barriers to entry but stringent regulations discourage new companies.
Bargaining power of buyers: Large healthcare providers can demand lower prices but need for accurate diagnosis gives companies power.
Bargaining power of suppliers: Diagnostic equipment makers face competition but proprietary technologies increase switching costs.
Threat of new substitutes: Other preeclampsia screening methods emerge but none match the predictive power and convenience of biomarker tests.
Competitive rivalry: Intense competition to develop accurate rapid tests and win contracts from hospitals and clinics.

SWOT Analysis
Strengths: Advancements in biomarker identification and detection technologies. Growing demand for minimally invasive diagnostic tests.
Weaknesses: High R&D costs and regulatory requirements. Reimbursement challenges in some regions.
Opportunities: Rising preeclampsia incidence worldwide offers scope for expanded sales coverage. Potential to detect other pregnancy complications.
Threats: Threat from low-cost alternatives in developing nations. Stringent guidelines may delay approvals or increase compliance costs.

Key Takeaways
The global Preeclampsia Diagnostics Market is expected to witness high growth at a CAGR of 11% over the forecast period due to increasing preeclampsia prevalence, growing awareness, and technological advancements.

North America dominates with over 30% market share owing to stringent regulatory norms, developed healthcare infrastructure, and presence of global market leaders. Asia Pacific exhibits fast adoption and promises highest growth led by China, Japan and India.

Key players operating in the Preeclampsia Diagnostics Market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, and Miraculins Inc. Companies are investing in biomarker research and launching affordable solutions to penetrate developing markets.